{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4000000","upperLimit":"10000000","value":"6000000"},{"groupId":"OG001","lowerLimit":"4000000","upperLimit":"21000000","value":"5000000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Calculate the median total CD34+ cell counts across all leukapheresis sessions following TG 0054 administration alone and in combination with G-CSF mobilization in order to evaluate the pharmacodynamics (PD) of TG-0054 by determining circulating CD34+ cell counts in peripheral blood.","dispersionType":"Full Range","groups":[{"description":"Patients followed administration of TG-0054 (3.14 mg/kg) alone and leukapheresis start from study day 1.","id":"OG000","title":"TG-0054 (3.14 mg/kg)"},{"description":"Patients followed administration of TG-0054 (3.14 mg/kg) combined with granulocyte colony-stimulating factor (G-CSF) and leukapheresis start from study day 8.","id":"OG001","title":"TG-0054 (3.14 mg/kg)+G-CSF"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"pre-dose(-2 to 0 h),2, 4 and 6 hr after dosing.","title":"Circulating CD34+ Cell Count in Peripheral Blood","type":"SECONDARY","unitOfMeasure":"cells/kg"}